S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry
Stephan A. Grupp,Zhen-Huan Hu,Yiyun Zhang,Amy K. Keating,Michael A. Pulsipher,Christine Philips,Steven P. Margossian,Joseph Rosenthal,Dana Salzberg,Deborah Schiff,Gregory A. Yanik,Kevin J. Curran,Andrew C. Harris,Peiman Hematti,Sarah Nikiforow,Patricia Steinert,Lan Yi,Raghav Chawla,Mary M. Horowitz,Eric Bleickardt,Marcelo C. Pasquini +20 more
TL;DR: The CIBMTR CT Registry was developed to collect long-term safety and efficacy information on recipients of cellular immunotherapies and it is utilized for a post marketing study of tisagenlecleucel in the real world setting and showed no association with best overall response.
Journal ArticleDOI
Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL
David L. Porter,Stephan A. Grupp,Michael Kalos,Alison W. Loren,Lester Lledo,Joan Gilmore,Michael C. Milone,Anne Chew,Bruce L. Levine,Carl H. June +9 more
TL;DR: Results show that in responding CLL pts the maximal fold elevation from baseline for IFN-γ was 89–298x, IL-6 6–40x, and IL2R 5– 25x, while no significant elevation in systemic levels of TNFα or IL2 were observed, while the timing for maximum cytokine elevation differed but in all cases correlated with peak T cell expansion in the PBMC.
Journal ArticleDOI
Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function
David M. Barrett,Nathan Singh,Ted J. Hofmann,Zachary Gershenson,Stephan A. Grupp,Stephan A. Grupp +5 more
TL;DR: It is demonstrated that IL-6 as part of CRS is produced by APCs and not T cells in response to CART19 mediated killing of leukemia, and that Cart19 cells do not seem affected by the presence of C RS cytokines either in transcriptional profile or killing potential.
Journal ArticleDOI
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study
Christopher C. Dvorak,Prakash Satwani,Elliot Stieglitz,Mitchell S. Cairo,Ha Dang,Ha Dang,Qinglin Pei,Yun Gao,Donna A. Wall,Tali Mazor,Adam B. Olshen,Joel S. Parker,Samir B. Kahwash,Betsy A. Hirsch,Susana C. Raimondi,Neil S. Patel,Micah Skeens,Todd M. Cooper,Parinda A. Mehta,Stephan A. Grupp,Mignon L. Loh +20 more
TL;DR: ASCT1221 was designed to test whether the potentially less‐toxic myeloablative conditioning regimen containing busulfan‐fludarabine (Bu‐Flu) would be associated with equivalent outcomes in patients with juvenile myelomonocytic leukemia.
Journal ArticleDOI
Subcutaneous immunoglobulin replacement following CD19‐specific chimeric antigen receptor T‐cell therapy for B‐cell acute lymphoblastic leukemia in pediatric patients
Danielle E. Arnold,Shannon L. Maude,Shannon L. Maude,Colleen Callahan,Amanda M. DiNofia,Amanda M. DiNofia,Stephan A. Grupp,Stephan A. Grupp,Jennifer Heimall,Jennifer Heimall +9 more
TL;DR: Patients maintained on subcutaneous immunoglobulin replacement for persistent B‐cell aplasia and agammaglobulinemia following CD19‐targeted chimeric antigen receptor T‐cell therapy for B‐ cell lymphoblastic leukemia were recommended to maintain a goal IgG level > 1000 mg/dL to provide optimal protection.